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RRM1 is a determinant of gemcitabine eﬃcacy in cancer patients. However, the precision of predicting tumor response based on
RRM1 levels is not optimal. We used gene-speciﬁc overexpression and RNA interference to assess RRM1’s impact on diﬀerent
classes of cytotoxic agents, on drug-drug interactions, and the modulating impact of other molecular and cellular parameters.
RRM1 was the dominant determinant of gemcitabine eﬃcacy in various cancer cell lines. RRM1 also impacted the eﬃcacy of
other antimetabolite agents. It did not disrupt the interaction of two cytotoxic agents when combined. Cell lines with truncation,
deletion, and null status of p53 were resistant to gemcitabine without apparent relationship to RRM1 levels. Pemetrexed and
carboplatin sensitivity did not appear to be related to p53 mutation status. The impact of p53 mutations in patients treated with
gemcitabine should be studied in prospective clinical trials to develop a model with improved precision of predicting drug eﬃcacy.
1.Introduction
The regulatory subunit of ribonucleotide reductase (RRM1)
has been identiﬁed as the key molecular determinant of
gemcitabine eﬃcacy both in vitro and in vivo [1–7]. Human
lung and pancreatic cancer cell lines and a serially trans-
planted mouse colon cancer made resistant to gemcitabine
through continuous exposure to increasing amounts of
drug overexpressed RRM1 [1, 3, 5]. RRM1 overexpression
through transfection of a lung cancer cell line likewise
resulted in gemcitabine resistance [4]. Reduction of RRM1
expression through RNA interference abrogated the induced
gemcitabine resistance and increased drug sensitivity in
otherwise sensitive cell lines [4, 5].
An association between intratumoral RRM1 levels and
eﬃcacy of systemic therapy that includes gemcitabine
as a single-agent or in combination with a platinum-
agent or pemetrexed has also been reported [8]. How-
ever, the addition of a vinca-alkaloid (vinorelbine) to a
gemcitabine-containing combination in patients with non-
smallcell lung cancer (NSCLC) appeared to abrogate the
RRM1-gemcitabine eﬃcacy association [2]. Although gem-
citabine therapy is statistically signiﬁcantly more eﬃcacious
in patients with low tumoral RRM1 levels, the scatter plots
reported and correlation coeﬃcientsarelessthanoptimalfor
precise predictions on whether or not gemcitabine will result
in tumor shrinkage in individual patients [7].
Here we studied associations between RRM1 expression
levels and sensitivities to frequently used chemotherapeutic
single agents and combinations as well as cell lines charac-
t e r i s t i c si na ne ﬀort to determine the impact of RRM1 on
relevant classes of agents and to identify parameters that
might modify the RRM1-gemcitabine eﬃcacy interaction.
2.MaterialandMethods
2.1. Cell Lines and Culture Conditions. The cell lines
used in this study were obtained from the American
Type Culture Collection (ATCC) or the originators. MCF7
human mammary adenocarcinoma cells were maintained
in MEM-α supplemented with 10% fetal bovine serum,
penicillin/streptomycin, nonessential aminoacids (0.1mM),
sodium pyruvate (1mM), sodium bicarbonate (1.5g/L), and
bovine pancreatic insulin (Sigma Aldrich, 0.01mg/mL). All
NSCLC cell lines and HCT8 (human colonic adenocarci-
noma cells) were maintained in RPMI 1640 supplemented2 Journal of Nucleic Acids
with L-glutamine (2mM), penicillin/streptomycin (100
units/100μg per mL), and 10% fetal bovine serum. Unless
otherwise speciﬁed, all reagents were purchased from Gibco
(Invitrogen). All cell lines were free of mycoplasma con-
tamination (Stratagene), their authenticity was conﬁrmed
by DNA ﬁngerprint analysis, and testing was performed
within 6 months of in vitro propagation for experiments
described herein. They were harvested at 70% conﬂuency for
subsequent experiments.
2.2.RRM1andp53TransfectedCellLines. We have generated
three human cell line models derived from lung (H23),
breast (MCF7), and colon (HCT8) cancers, with increased
and decreased RRM1 expression by stable transfection as
previously described [9]. In general, stably overexpressing
RRM1 cell lines and their controls were generated by trans-
fection with full-length human RRM1 cDNA cloned into the
expression plasmid pCMV-Tag2 (Stratagene). Stably down-
regulated RRM1 cell lines were generated by transfection
with pSUPER-GFP (oligoEngine) containing RRM1-speciﬁc
target sequence (GACGCTAGAGCGGTCTTAT) or, as a
control, scramble sequence that had no similarity to any
known gene using FuGENE HD (Roche Applied Science).
The overexpression and down regulation of RRM1 were
conﬁrmed by real-time RT-PCR and immunoblotting. A
stably TP53 wild-type expressing cell line (H358-p53+) was
generated by transfection with a pcDNA3 vector containing
full-length TP53 cDNA (a gift from Dr. Jiandong Chen).
2.3. Target Gene Expression Reduction. Dharmacon on-
TARGETplus Smartpool siRNA to TP53, ERCC1, and RRM1
(Dharmacon RNAi Technologies) were delivered to H23,
A549,H292,andH460NSCLCcelllinesusingLipofectamine
RNAiMAX (Invitrogen) following manufacturer’s instruc-
tions. Nontarget Pool siRNA was used as control.
2.4. Isolation of Total Cellular RNA and Real-Time PCR.
Total RNA was isolated from cultured cells with TRIzol
reagent (Invitrogen), and cDNA was synthesized with the
Superscript ampliﬁcation kit (Invitrogen). Quantitative real-
time PCR was employed to measure the expression of RRM1
using 18s-rRNA as internal reference standard. The RRM1
primers were forward AAGAGCAGCGTGCCA GAGAT,
reverse ACACATCAAAGACCAGTCCTGATTAG, and
probe 5 TTTGC TCTTTGGATTCCGGATCTCTTCA3 .
18s-rRNA was detected using commercial primers and
probes (Applied Biosystems). For each sample, the target
RRM1 and 18s-rRNA concentrations were determined by
interpolation to a standard curve. The normalized RRM1
quantity was then derived by dividing the RRM1 value by
the 18s-rRNA value.
2.5. Drug Sensitivity and In Vitro Proliferation Assay. The
following anticancer drugs were tested: gemcitabine and
pemetrexed (Eli Lilly), methotrexate, carboplatin, hydrox-
yurea,and5-ﬂuorouracil(SigmaAldrich);docetaxel(Sanoﬁ-
Aventis); cisplatin (Ben Venue Laboratory), vinorelbine
(Sicor), and etoposide (Bedford Laboratory). At the time of
use, the drugs were freshly prepared and diluted stepwise to
the desired concentration in the proper solvent or culture
medium.
Cell viability in response to various drugs was assessed
with a cell proliferation 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS) assay in 96-well plates (Corning). Brieﬂy, 1,000–
4,000 viable cells were seeded in triplicate in 100μLo f
growth medium and allowed to attach for 24h. The cells
were then continuously exposed to 0.01nM–1mM of each
drug (0.1nM–10mM for hydroxyurea) for 3–10 days.
Thereafter, cells were exposed to CellTiter96 AQueous One
Solution Reagent (Promega) for 2h at 37
◦C, and formazan
absorbance was measured at 490nm using a microplate
reader (Benchmark Plus, Bio-Rad). Each experiment was
repeated 3 times on diﬀerent days with separate preparations
of cells and drugs.
Alternately,drugactivitywasassessedusingtheCellTiter-
Blue viability assay in 384-well plates (Promega). In this
format, 800 or 1,200 cells (for 5-day or 3-day experiments,
respectively) were plated in each well by using a Precision
XS automated pipetting system (Bio-Tek Instruments) and
allowed to attach overnight at 37
◦C .T h er e s p e c t i v ed r u g s
and combinations were serially diluted in growth medium,
and 5μl were then added to wells. Four replicate wells
were used for each drug concentration and an additional
four control wells received media without drug. After 3
or 5 days of incubation, 5μl CellTiter-Blue solution was
added to each well. Cell viability was assessed by the ability
of the metabolically active cells to reduce resazurin to
the highly ﬂuorescent resoruﬁn. The resulting ﬂuorescence
(560Ex/590Em)wasmeasuredwithaSynergyHTmicroplate
reader (Bio-Tek Instruments).
For both, the 96-well and 384-well experiments, ﬂuo-
rescence data were transferred to a spreadsheet program to
calculate the percent viability relative to the replicate control
cell wells that did not receive drug. Data analysis for IC50
value calculations was performed using SigmaPlot (Systat
Software).
For drug combination experiments, the IC50 values
obtained from single drug assays were used to design the
experiments, and the cell viability assays were performed as
described above. The results were analyzed for synergistic,
additive, or antagonistic eﬀects using the combination index
(CI) method developed by Chou [10]. For the application of
this method, the drug concentration dilutions were used at
ﬁxed dose ratios (e.g., 50:1, 2:5, 1:250). Brieﬂy, the dose-
eﬀect curve for each drug alone was determined based on
experimental observations using the median-eﬀect principle
a n dc o m p a r e dt ot h ee ﬀect achieved with a combination of
two drugs to derive a CI value. The method involves plotting
dose-eﬀect curves, for each agent and their combination,
using the median-eﬀect equation: fa/fu = (D/Dm)m,w h e r e
D is the dose of the drug, Dm the dose required for a
50% eﬀect (equivalent to IC50), fa and fu the aﬀected and
unaﬀected fractions (fa = 1-fu), and m the exponent signify-
ing the sigmoidicity of the dose-eﬀect curve. The computer
software XLﬁt was used to calculate the values of Dm and
m. The CI used for the analysis of the drug combinationsJournal of Nucleic Acids 3
was determined by the isobologram equation for mutually
nonexclusive drugs that have diﬀerent modes of action:
CI = (D)1/(Dx)1 +( D)2/(Dx)2 +( D)1(D)2/(Dx)1(Dx)2,
where (Dx)1 and (Dx)2 in the denominators are the doses
(or concentrations) for drug 1 and drug 2 alone that gives
x% inhibition, whereas (D)1 and (D)2 in the numerators are
the doses of drug 1 and drug 2 in combination that also
inhibited x% (i.e., isoeﬀective). Combination indices CI < 1,
CI = 1, and CI > 1 indicate synergism, additive eﬀects, and
antagonism, respectively.
2.6. Immunoblotting and Antibody Reagents. Tumor cells
were cultured as described above. Crude cell extract proteins
w e r es u s p e n d e di nR I P Ab u ﬀer in the presence of a protease
inhibitorcocktail.Afterdeterminationoftheproteinconcen-
tration, extracts were separated on 8%–10% SDS-PAGE gels,
transferred to membranes, and the expression proﬁles ana-
lyzedbyimmunoblotting.Monoclonalantibodiesorantisera
to RRM1 (T-16, cat # sc-11733, lot # H0608), RRM2a (I-
15, cat # sc-10848, lot # G1806), RRM2b (N-16, cat # sc-
10840, lot # E2107), P38 (H-147, cat # sc-7149, lot # I149),
ERCC1 (FL-297, cat # sc-10785, lot # G1103), and MCM2
(N-19, cat # sc-9839, lot # I1907) were purchased from Santa
Cruz Biotechnology, and monoclonal antibody to TS (TS-
106, cat # MS-471-p1, lot # 471P708B) was from Anatomical
Pathology and to TP53 (p53, cat # 554293, lot # 0000045190)
from BD Bioscience. The bound antibody was detected
using the ECL detection system according to manufacturer’s
instructions (Amersham Pharmacia Biotech). The intensity
values of speciﬁc bands were quantiﬁed with a Personal Den-
sitometer SI (Molecular Dynamics). To compare expression
values among the diﬀerent cell lines, the target protein values
were normalized by comparison with the house keep gene β-
actin. These adjusted measures were then assigned the value
1.0 in cell line H23 to obtain relative adjusted values for all
other cell lines.
2.7. DNA Sequencing. DNA sequencing of the p53 and K-
ras genes was done using the Applied Biosystems 3130XL
genetic analysis system. Genomic DNA from tumor cell lines
wasobtainedwithPureLinkGenomicDNAkits(Invitrogen).
Exons of the p53 gene were ampliﬁed using previously
reported primers with minor modiﬁcations [11]. For K-ras,
codon 12 and 13 were sequenced bidirectionally. For p53,
all 11 exons were sequenced in both directions. All sequence
data were conﬁrmed with publicly available information.
3. Results
3.1. Impact of RRM1 Modulation on Diﬀerent Classes of
Agents. We had previously described the stably transfected
RRM1 up- and down-regulated clones of NSCLC cell line
H23 [4]. To expand and complement this model, we
generated similar clones for the human breast cancer cell line
MCF7 and colon cancer cell line HCT8. RRM1 expression at
the mRNA and protein level was variable among clones. For
drug testing, clones with a greater than 2-fold increase (for
up regulation) or a greater than 2-fold decrease (expression
<50% of control) in RRM1 expression at the mRNA and
protein level were selected (Figures 1(a), 1(b)).
To evaluate the impact of RRM1 on diﬀerent classes of
chemotherapeutic agents, clones with high and low RRM1
levels and their respective controls were treated with each
agent over a broad range of concentrations. Dose response
blots were generated and mean IC50 values calculated from
at least 3 independent experiments (Table 1). For all agents,
a dose-dependent inhibition was observed (Figure 1(c)). The
relative impact of RRM1 was assessed by dividing the IC50
values of RRM1 modulated clones with those of control
clones (Table 1). High RRM1 levels resulted in resistance and
low levels in sensitivity to gemcitabine and 5-FU in NSCLC
cell line H23, breast cancer cell line MCF7, and colon cancer
cell line HCT8. Similarly, high RRM1 induced resistance to
methotrexate and pemetrexed in H23, but low levels induced
only a minimal increase in sensitivity. In MCF7 and HCT8,
no eﬀect on methotrexate was observed and the eﬀect on
pemetrexedwasintheoppositedirection;thatis,highRRM1
was associated with increased sensitivity and low levels with
resistance. Hydroxyurea was not aﬀected by RRM1 in H23,
but low levels resulted in increased sensitivity in MCF and
HCT8.
For the platinum agents cisplatin and carboplatin, high
or low RRM1 induced minimal resistance or sensitivity in
H23 and had no consistent impact in MCF7 and HCT8.
There was no observable relationship between RRM1 levels
and eﬃcacy of docetaxel, vinorelbine, and etoposide in all
three model systems.
3.2. Impact of RRM1 Modulation on Drug Combinations in
H23. We next assessed if RRM1 modulation would impact
on the cytotoxicity of combinations of two agents. For
this, we chose four commonly used chemotherapy doublets
focused on antimetabolites in NSCLC; that is, gemcitabine +
carboplatin, gemcitabine + docetaxel, gemcitabine + peme-
trexed, and pemetrexed + carboplatin. The assays and
analyseswereasdescribedusingsynchronousdrugexposure,
and a combination index (CI) was calculated from three
separate experiments (Table 2). We observed synergy for
the two platinum combinations and antagonism for the
two nonplatinum combinations. RRM1 expression levels
did not abrogate or reverse these interactions, although the
CI values diﬀered slightly among the RRM1 modulated
clones.
3.3. Down Regulation of RRM1 by RNA Interference Increases
Gemcitabine Sensitivity in Other NSCLC Cell Lines. To
conﬁrm if RRM1 downregulation would increase gemc-
itabine eﬃcacy in other NSCLC cell lines, we transfected
20nM of target-speciﬁc short interfering RNA (siRNA) and
nonspeciﬁc random siRNA for control purposes into cell
lines A549, H292, and H460. Since ERCC1 (excision repair
cross complementing group 1) expression levels in lung
cancers are positively correlated with those of RRM1, we
also used ERCC1-speciﬁc siRNA as a control. Immunoblot
analysis demonstrated eﬃcient knock-down of the speciﬁc
target proteins RRM1 and ERCC1 in all three cell lines4 Journal of Nucleic Acids
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Figure 1: Modiﬁcation of RRM1 expression by stable transfection with RRM1 and shRRM1 expression vectors in cell lines H23, MCF7,
and HCT. Wt, wild-type cell lines, R1, clones of cell lines transfected with RRM1; Ct, clones transfected with an out-of-frame RRM1 vector;
shR1, clones transfected with a small hair-pin RRM1 vector; shCt, clones transfected with a random control small hair-pin vector. (a)
RRM1 protein (red) and mRNA (green) expression in stably transfected clones of H23, MCF7, and HCT8. (b) Western blots of H23, MCF7,
and HCT8 clones. (c) Cytotoxicity of MCF7 clones following gemcitabine treatment for 6 days. Each point is the mean of at least three
independent experiments. The dashed line indicates the 50% survival fraction.
(Figure 2(a)). We observed a 5- to 20-fold increase in gem-
citabine eﬃcacy with RRM1 down-regulation (Figure 2(b));
carboplatin eﬃcacy was not notably aﬀected.
3.4. Endogenous RRM1 Expression, Drug Sensitivity, and Cell
Line Characteristics in a Panel of NSCLC Cell Lines. Since
tumoral RRM1 levels and therapeutic eﬃcacy of chemother-
a p yv a ryw i d e l y[ 7], we sought to investigate parameters that
might inﬂuence the RRM1-gemcitabine eﬃcacy interaction.
For this, we used a random series of 26 NSCLC cell lines
with a diverse range of properties. In these cell lines,
we determined the endogenous levels of RRM1, RRM2a,
RRM2b, and other molecules associated with nucleotide
metabolism and cell proliferation in exponentially growing,
subconﬂuent, and unsynchronized cultures. The relative
expression levels were determined by densitometry of spe-
ciﬁc bands on a single, large immunoblot adjusted for β-
actin expression and normalized to the level of each target
protein in cell line H23 (levels arbitrarily set to 1.00).
We also determined the p53 and K-ras mutational status,6 Journal of Nucleic Acids
Table 2: Impact of RRM1 expression on drug combinations.∗
Drug combination
Clones of H23
H23-Ct H23-R1 H23-shCt H23-shR1
control R1 increased control R1 decreased
Gemcitabine & Carboplatin 0.93 (+/−) 0.83 (++) 0.56 (+++) 0.72 (++)
Gemcitabine & Docetaxel 2.8 (−−− )2 . 1 ( −−− )3 . 1 ( −−− )1 . 4 ( −−)
Gemcitabine & Pemetrexed 1.5 (−−− )1 . 4 ( −−)1 . 7 ( −−− )1 . 7 ( −−− )
Pemetrexed & Carboplatin 0.79 (++) 0.94 (+/−) 0.73 (++) 0.64 (+++)
∗The combination index (CI) was calculated according to Chou [10] and averaged from three separate experiments. Combination indices CI < 1, CI = 1,
and CI > 1 indicate synergism, additive eﬀects, and antagonism, respectively. Ranking symbols within parenthesis indicate relative antagonism, additivity, or
synergy: (−−− : strong antagonism; −−: moderate antagonism;+/−: nearly additive; ++: moderate synergy; +++: strong synergy).
the doubling time (calculated with CurveExpert software),
and the IC50 and maximum achievable cytotoxicity with
gemcitabine, pemetrexed, and carboplatin (Table 3).
We did not observe a statistically signiﬁcant correlation
between RRM1 levels and the gemcitabine IC50 values
(Spearman rank correlation coeﬃcient r = 0.10, P = .65).
There was also no signiﬁcant correlation between RRM1
levels and those of the other 7 proteins analyzed or the
doublingtime. Ofnote,TSlevelsandpemetrexedIC50 values
were not correlated (r = 0.003, P = .99), neither were
ERCC1 levels and carboplatin IC50 values (r = 0.07, P =
.75).
However, the median IC50 values for gemcitabine were
approximately 10-fold higher in the group of 8 cell lines with
p53 truncations, deletions, or null status (0.3μM) compared
to the 18 cell lines without such mutations (0.03μM; P = .06
by rank sum test). A similar trend was not observed for
pemetrexed or carboplatin. The K-ras mutation status did
n o ti m p a c te ﬃcacy of the three agents tested.
The doubling time of cell lines was signiﬁcantly corre-
lated with gemcitabine IC50 values; that is, cell lines with
long doubling times had higher IC50 values (Spearman rank
correlation coeﬃcient r = 0.63, P<. 001), and it was not
correlated with the IC50 values of pemetrexed or carboplatin.
3.5. TP53 Levels and Gemcitabine Cytotoxicity. In order to
studyifwild-typep53contributestogemcitabineeﬃcacy,we
deliveredp53-speciﬁcsiRNAandnonspeciﬁcrandomsiRNA
to cell lines H23, A549, H292, and H460. We obtained near
complete knock down in A549 and H292, a partial reduction
in H460, and a minimal reduction in H23 using 20nM
siRNA concentrations and 24hrs of exposure (Figure 3).
Higher siRNA concentrations and longer exposure times
did not yield better p53 reduction in H23 and H460.
Gemcitabine IC50 values increased 2.0-fold in A549 (p53
wild-type)to3.4-foldinH292(p53wild-type)andremained
essentiallyunchangedinH23(1.3-fold,p53M246Imissense)
and H460 (1.1-fold, p53 wild-type).
To corroborate this result, we used the p53-null cell line
H358anditsstablytransfectedandwild-typep53-expressing
counterpart H358p53+ (Figure 4). We observed a statistically
signiﬁcant reduction in the gemcitabine IC50 from 15.3nM
in H358 to 10.7nM in H358p53+ (P = .03 by t-test; values
are means of three independent experiments using 5 days
of exposure), while the IC50 values for pemetrexed and
carboplatinwerenotsigniﬁcantlydiﬀerentbetweenthesecell
lines.
4. Discussion
The use of unselected double-agent chemotherapy has
resulted in an approximately 50% improvement in overall
median survival of patients with advanced NSCLC [12].
The only criteria currently used for selection of agents are
histology [13], toxicity proﬁles, and convenience of delivery.
Two recent prospective clinical trials have demonstrated the
feasibility of selecting individualized chemotherapy based
on RRM1 and/or ERCC1 expression levels in tumor biopsy
specimens [14, 15]. Both trials also reported favorable
response rates for patients receiving molecularly-based
selected compared to unselected therapy. In two additional
prospective trials in patients with metastatic stage III or stage
IV disease, a statistically signiﬁcant association between the
tumoral expression levels of RRM1 and the magnitude of
change in tumor burden with gemcitabine single-agent or
gemcitabineandcarboplatindouble-agenttherapyhavebeen
reported; that is, the lower the levels the better the response
[4, 7].
The antitumoral activity of gemcitabine is a result of
at least two separate actions. One is a presumed direct
interactionwithRRM1,witharesultingreductionofribonu-
cleotide reductase function and deoxynucleotide levels, and
the other is incorporation into newly synthesized DNA,
with a resulting chain termination. It is the presumed
interaction with RRM1 that explains the direct and linear
associationbetweenRRM1levelsandgemcitabineIC50 levels
in experimental model systems. However, as can be gleaned
from the published scatter plots depicting the association
between intratumoral RRM1 levels and tumor response in
cancer patients [4, 7], it is diﬃcult to be precise in predicting
whether an individual patient will actually derive beneﬁt
from the selected therapy.Journal of Nucleic Acids 7
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Figure 2: Knock-down of RRM1 and ERCC1 expression in three NSCLC cell lines by RNA interference and impact on gemcitabine eﬃcacy.
(a) Western blots showing that RRM1-speciﬁc siRNA reduced RRM1 protein expression to undetectable levels, while random control and
ERCC1-speciﬁcsiRNAsdidnotaﬀectRRM1expression.Likewise,ERCC1-speciﬁcsiRNAreducedERCC1proteinexpressiontoundetectable
levels, while random control and RRM1-speciﬁc siRNAs did not aﬀect ERCC1 expression. (b) IC50 values of gemcitabine cytotoxicity in cell
linesA549,H292,andH460.Wt,wild-typecelllines;si-control,celllinestransfectedwithnonspeciﬁcsiRNA;si-ERCC1;celllinestransfected
with ERCC1-speciﬁc siRNA; si-RRM1, cell lines transfected with RRM1-speciﬁc siRNA.
Given the molecular complexity of NSCLC, this is not
surprising and strongly suggests that a variety of other
tumor-speciﬁc and host-speciﬁc parameters substantially
impact the gemcitabine-RRM1 interaction. Our results in
a lung, breast, and colon cancer cell line with genetically
modiﬁed RRM1 levels demonstrate that RRM1 expression
levels are the dominant determinant of gemcitabine eﬃ-
cacy despite diverse molecular backgrounds. This result is
consistent with prior reports of increased RRM1 levels in
pancreatic and colon cancer models upon induction of
gemcitabine resistance [3, 5]. In our cell line models, we
further demonstrate that RRM1 levels can impact eﬃcacy of
other cytotoxic agents in the class of antimetabolites. Since
this eﬀect was not observed in all cell lines, other parameters
may dominate over the interaction between RRM1 and
5FU, pemetrexed, and methotrexate. For instance, a signif-
icant role for TS on 5FU and dihydrofolate reductase on
methotrexate eﬃcacy has been established, and a role for
TS and other enzymes involved in nucleotide synthesis on
pemetrexed eﬃcacy is evolving. However, an explanation for
the increased pemetrexed sensitivity of RRM1 transfected
MCF7 and HCT8 cell lines is elusive. We also demonstrate
that RRM1 levels do not impact on eﬃcacy of spindle-
disrupting agents or etoposide, which are frequently used
in lung cancer therapy. In fact, an earlier report on a small
subset of patients treated with vinorelbine, gemcitabine, and
platinum had suggested that the addition of vinorelbine may
abrogate the therapeutic beneﬁt of gemcitabine in patientsJournal of Nucleic Acids 9
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Figure 3: Western blots of knock-down of TP53 expression in four NSCLC cell lines by RNA interference. TP53-speciﬁc siRNA reduced
TP53 protein expression to undetectable levels in A549 and H292 and greater then 10-fold in H23 and H460, while random control siRNA
did not aﬀect TP53 or RRM1 expression.
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Figure 4: Western blots of cell line H358. There is no detectable
TP53 expression in wild-type cells; while transfected cells clearly
show TP53 expression.
with low levels of RRM1 expression [2]. Our in vitro results
on combination therapy suggest that RRM1 does not disrupt
drug-drug interactions when gemcitabine is combined with
carboplatin, docetaxel, or pemetrexed.
Since RRM1 is often combined with ERCC1 in trials
seeking to enhance therapeutic eﬃciency through agent
selection and because both molecules are frequently coex-
pressed [2, 4, 7, 16, 17], we tested in three cell lines if ERCC1
expression reduction through RNA interference would alter
gemcitabine eﬃcacy and found no evidence for this.
Using a panel of lung cancer cell lines with diverse
features and molecular characteristics, we identiﬁed two
variables that signiﬁcantly impacted gemcitabine eﬃcacy
without being associated with RRM1 levels. We found that
cell lines with functional p53-impairing mutations, that
is, null, truncation, and deletion mutations, displayed a
pattern of resistance to gemcitabine. We corroborated this
result through transfection of wild-type p53 into a null
cell line (H358), which resulted in a statistically signiﬁcant
improvement in gemcitabine eﬃcacy, and through abroga-
tion of p53 by RNA interference in other cell lines, which
resulted in gemcitabine resistance. This was not explained
by RRM1 expression levels, since no association between
RRM1 levels and p53 was observed. In contrast, pemetrexed
and platinum eﬃcacy did not seem to be inﬂuenced by p53
expression modulation. To our knowledge, the impact of p53
mutations on gemcitabine eﬃcacy has not been studied in
clinical trials. It is important to corroborate these results
in prospective trials since a potential clinical implication
might be that tumoral RRM1 levels may not be predictive
of gemcitabine eﬃcacy in patients whose tumors harbor
functionally signiﬁcant p53 mutations.
Finally, our in vitro data demonstrated a statistically
signiﬁcant correlation between gemcitabine eﬃcacy and the
doubling time; that is, cell lines with long doubling times
were more resistant to gemcitabine. Although we used a 4-
daycontinuous exposuretogemcitabine,whichshouldallow
for all cells to proceed through at least one complete cell
cycle, we cannot exclude that this result is caused by the
experimental conditions. However, a similar phenomenon
was not observed for pemetrexed or carboplatin, which
suggests that a true association between the speed of cellular
replicationandgemcitabineeﬃcacyexists.Itisnotexplained
by RRM1 expression levels or p53, since a signiﬁcant correla-
tion between these and the doubling time was not observed.
However, we had previously reported that overexpression of
RRM1 through stable transfection in cell lines resulted in
slow growth predominantly through G2 arrest [18]. It is thus
possible that the increased gemcitabine eﬃcacy is a result of
a decreased ability of cells to repair newly synthesized DNA
with incorporated 2 ,2  -diﬂuorodeoxycytidine that leads to
chain termination [19].10 Journal of Nucleic Acids
5. Conclusions
We demonstrated a dominant role for RRM1 in gemcitabine
eﬃcacy and also a role in eﬃcacy of other antimetabolites
in selected cell lines. RRM1 did not disrupt the interaction
between gemcitabine and other cytotoxic agents when com-
bined. The mutational status of p53 and cell line doubling
time were signiﬁcant and independent determinants of
gemcitabine eﬃcacy. Their impact on gemcitabine eﬃcacy in
patients with lung cancer in the context of RRM1 expression
requires investigations in prospective clinical trials.
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